logo

For the Inventor, By the Inventor

La Chaux-de-Fonds, Switzerland

Rhizen Pharmaceuticals Sa


USPTO Granted Patents = 51

% Expired Patents = 60.8



Forward Citations = 131

Loading Chart...
Loading Chart...

17 inventors (with patents filed for the assignee):

goldMedal Srikant Viswanadha (36 out of 39 patents)

silverMedal Meyyappan Muthuppalaniappan (31 out of 32 patents)

bronzeMedal Swaroop K Vakkalanka (29 out of 34 patents)

4.  Govindarajulu Babu (19 out of 22 patents)

5.  Swaroop Kumar V S Vakkalanka (15 out of 15 patents)

6.  Prashant Kashinath Bhavar (14 out of 16 patents)

7.  Dhanapalan Nagarathnam (14 out of 61 patents)

8.  Gayatri Swaroop Merikapudi (13 out of 13 patents)

9.  Swaroop K V S Vakkalanka (5 out of 6 patents)

10.  Michael S Weiss (2 out of 4 patents)

11.  Hari P Miskin (2 out of 3 patents)

12.  Peter Sportelli (2 out of 4 patents)

13.  Jayaraman Venkat Raman (2 out of 5 patents)

14.  Kanthikiran V S Varansi (1 out of 1 patent)

15.  Merikapudi Gayatri Swaroop (1 out of 1 patent)


Core Competencies:
PDE4 Inhibitors
PI3K Delta Inhibitors
Kinase Modulators
c-Met Protein Kinases
Calcium Release-Activated Channels
Glutaminase Inhibitors
Anti-CD20 Antibody
Bicyclic Compounds
GPR-119
Immunomodulators
Dual PI3K Inhibitors
Chromen-4-One Compounds

51 patents:

1. 11066402 - 3,5-disubstituted-3H-imidazo[4,5-b]pyridine and 3,5-disubstituted-3H-[1,2,3]triazolo[4,5-B] pyridine compounds as modulators of c-Met protein kinases (2021-07-20),
2. 11065236 - Pharmaceutical compositions containing a PDE4 inhibitor and a PI3 delta or dual PI3 delta-gamma kinase inhibitor (2021-07-20),
3. 11020399 - Intermediates useful in the synthesis of compounds as modulators of protein kinases (2021-06-01),
4. 10981919 - Selective PI3K delta inhibitors (2021-04-20),
5. 10966977 - Combination of anti-CD20 antibody, P13 kinase-delta selective inhibitor, and BTK inhibitor to treat b-cell proliferative disorders (2021-04-06),
6. 10947244 - Forms of a PI3K delta selective inhibitor for use in pharmaceutical formulations (2021-03-16),
7. 10851107 - Dual selective P13 delta and gamma kinase inhibitors (2020-12-01),
8. 10786504 - Method of treatment and compositions comprising a dual PI3K delta-gamma kinase inhibitor and a corticosteroid (2020-09-29),
9. 10729768 - Combination of anti-CD20 antibody and PI3 kinase selective inhibitor (2020-08-04),
10. 10668051 - Modulators of calcium release-activated calcium channel (2020-06-02),
11. 10611759 - Glutaminase inhibitors (2020-04-07),
12. 10590129 - 3,5-disubstituted-3H-imidazo[4,5-B]pyridine and 3,5-disubstituted-3H-[1,2,3]triazolo[4,5-B] pyridine compounds as modulators of protein kinases (2020-03-17),
13. 10570142 - Selective PI3K delta inhibitors (2020-02-25),
14. 10538501 - Kinase modulators (2020-01-21),
15. 10442783 - 2,3-disubstituted chromen-4-one compounds as modulators of protein kinases (2019-10-15),
Rhizen Pharmaceuticals SA, based in La Chaux-de-Fonds, Switzerland, specializes in the development of innovative pharmaceutical compositions targeting various diseases. The company focuses on advanced therapeutic areas, particularly in oncology and immunology, leveraging core technologies such as PDE4 inhibitors, PI3K delta inhibitors, and kinase modulators. Rhizen's research encompasses a range of mechanisms, including c-Met protein kinases and calcium release-activated channels, aiming to address unmet medical needs through novel drug candidates.
Profile summary based on public USPTO records.

logo

Company Badge

USPTO Data Jan 1 1976 - Sep 29 2026

Rhizen Pharmaceuticals Sa
51 Patents

#3 in La Chaux-de-Fonds

#290 in Switzerland

#13,753 in the World

La Chaux-de-Fonds, CH
La Chaux-de-Fonds, Switzerland

Rhizen Pharmaceuticals Sa

Forward Citations = 131

17 inventors:

goldMedal Srikant Viswanadha (36 out of 39 patents)

silverMedal Meyyappan Muthuppalaniappan (31 out of 32 patents)

bronzeMedal Swaroop K Vakkalanka (29 out of 34 patents)

4.  Govindarajulu Babu (19 out of 22 patents)

5.  Swaroop Kumar V S Vakkalanka (15 out of 15 patents)

Please report any incorrect information to [email protected]
Loading…